Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10591348 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL313049 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL3862762 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL1116755 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL3868201 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL3857775 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL7994751 | 1.00 | RAB9A (0.39) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL10591685 | 0.97 | RAB9A (0.35) | RAB9APTPN7HMGCRRECQLTDP1 | |
| SCHEMBL291632 | 0.97 | — | — | |
| SCHEMBL9211208 | 0.93 | RECQL (0.41) | RAB9APTPN7HMGCRRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050152959-A1 | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell | TRANSGENE S. A. (FR) | 2005-07-14 | — | — | US | disclosed |
| US-20050112187-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TRANSGENE S.A. (FR) | 2005-05-26 | — | — | US | disclosed |
| EP-1465597-A2 | USE OF A LYSOLIPID FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL | TRANSGENE S.A. (FR) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003052095-A2 | USE OF A LYSOLIPID FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL | TRANSGENE S.A. (FR) | 2003-06-26 | — | — | WO | disclosed |
| EP-1289568-A2 | COMBINATION PRODUCT FOR CARRYING OUT A CYTOTOXIC TREATMENT IN A MAMMAL | TRANSGENE S.A. (FR) | 2003-03-12 | — | — | EP | disclosed |
| US-20020025941-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TRANSGENE S.A. (FR) | 2002-02-28 | — | — | US | disclosed |
| WO-2001095946-A2 | COMBINATION PRODUCT FOR CARRYING OUT A CYTOTOXIC TREATMENT IN A MAMMAL | TRANSGENE S.A. (FR) | 2001-12-20 | — | — | WO | disclosed |
| US-4935520-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0138559-B1 | KETOALKYLPHOSPHOLIPIDS AND THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-08-23 | — | — | EP | disclosed |
| US-4649203-A | ANTITUMOR, FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0108565-A2 | Phospholipids, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152959-A1 | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell | LPCAT1, LPCAT3, LCLAT1 | RAB9A 2910/4885PTPN7 3174/4885HMGCR 2166/4885 |
| US-20050112187-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TYMP, PHOSPHO1, PIGS | RAB9A 2807/4885PTPN7 4309/4885HMGCR 3066/4885 |
| US-20020025941-A1 | Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal | TYMP, PHOSPHO1, PIGS | RAB9A 2807/4885PTPN7 4309/4885HMGCR 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.